Compare JILL & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JILL | NBP |
|---|---|---|
| Founded | 1959 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.5M | 205.9M |
| IPO Year | 2017 | 2019 |
| Metric | JILL | NBP |
|---|---|---|
| Price | $24.42 | $1.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $23.75 | $9.00 |
| AVG Volume (30 Days) | 183.6K | ★ 571.9K |
| Earning Date | 09-09-2026 | 08-20-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $596,549,000.00 | N/A |
| Revenue This Year | $1.15 | N/A |
| Revenue Next Year | $3.17 | N/A |
| P/E Ratio | $17.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.41 | $1.32 |
| 52 Week High | $25.00 | $5.19 |
| Indicator | JILL | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 69.95 | 28.73 |
| Support Level | $22.86 | N/A |
| Resistance Level | N/A | $1.67 |
| Average True Range (ATR) | 0.84 | 0.06 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 76.64 | 19.40 |
J.Jill Inc is a national lifestyle brand that provides apparel, footwear, and accessories. The company's products are marketed under the J.Jill brand name and sold through its two channels: its e-commerce platform and catalog (Direct) and its retail stores (Retail). J.Jill caters to a distinctive set of women, typically forty-five years and older, offering them various apparel products, footwear, and accessories, comprising shirts, dresses, tops and tees, sweaters, pants and jeans, jewelry, bags, belts, shoes, scarves, etc. The company's operating segments consist of its Retail channels, which derive maximum revenue, and Direct channels. Geographically, the majority of its revenue is derived from the United States.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.